Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
TAUSSIG Hints at Fewer CV Events on Evolocumab in Homozygous FHNo control group, but also no deaths and only four CV events in 1.7 years in 106 patients on the PCSK9 inhibitor. "Which is
remarkable" in HoFH, says a researcher; still, all urge caution interpreting the results.
Medscape Medical News, Jun 2, 2016
Insulin-Statin-PCSK9 Links Point to New Treatment HorizonsAn intricate dance with the PCSK9 molecule played out by statins, diabetes, and risk markers may explain the prowess of evolocumab
and alirocumab on LDL-C and points to a hypothetical use for the agents.
Medscape Medical News, Jun 17, 2016
HDL Subtypes Mediate Bariatric Surgery's Metabolic BenefitsIt's partly why dieting doesn't match surgery's favorable HDL and LDL effects: they depend more on changes in lipoprotein
profile, therefore function, than on overall levels, say several new reports.
